Amyloid Beta 1-42/1- 40 P.2.7.13

Amylola Beta 1-42/1-4							1					
Studies	Design	Total N	Sens (95%CI)	Spec (95%CI)	Measur e	Summary of findings (95%CI)	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Quality
SECONDARY CARE												
3 studies (Dumurgier 2015 (Lille); Dumurgier 2015 (Paris); Dumurgier 2015 (Montpellier))	3 × prospective	367	0.83 (0.60, 0.94)	0.77 (0.66, 0.85)	LR+	3.33 (2.31, 4.78)	V. serious	Not serious	Not serious	Not serious		LOW
					LR-	0.22 (0.09, 0.54)	V. serious	Serious	Not serious	Serious	-	VERY LOW

Notes on risk of bias

Dumurgier 2015: The reference standard diagnosis included consideration of the CSF results; the test cut offs were not pre-specified; patients with unknown clinical diagnoses or MCI were excluded from the study and the timing of the reference and index tests is unclear.

Additional notes: the Dumurgier study had 3 independent data sets from 3 different clinics.

[©] NICE 2018. All rights reserved. See Notice of rights.